Abstract
Neurontin (Gabapentin) is indicated as an add-on treatment of partial epileptic seizures. Clinical studies demonstrating the efficacy of Neurontin as monotherapy are currently on going. This article describes the design of 2 clinical trials of Gabapentin as monotherapy for epileptic seizures.
MeSH terms
-
Acetates / adverse effects
-
Acetates / therapeutic use*
-
Amines*
-
Anticonvulsants / adverse effects
-
Anticonvulsants / therapeutic use*
-
Cyclohexanecarboxylic Acids*
-
Dose-Response Relationship, Drug
-
Double-Blind Method
-
Drug Administration Schedule
-
Electroencephalography / drug effects
-
Epilepsies, Partial / drug therapy*
-
Epilepsy, Complex Partial / drug therapy*
-
Gabapentin
-
Humans
-
Randomized Controlled Trials as Topic
-
Research Design
-
Treatment Outcome
-
gamma-Aminobutyric Acid*
Substances
-
Acetates
-
Amines
-
Anticonvulsants
-
Cyclohexanecarboxylic Acids
-
gamma-Aminobutyric Acid
-
Gabapentin